Pharma Pulse 9/13/24: Black Patients Have Greater Risk of Dying From GVHD, Making the Leap from Pharmaceuticals to Private Equity & more

Making the Leap from Pharmaceuticals to Private Equity, Venture Capital

A Harvard Business School Healthcare Alumni Association Q&A with Jeremy Goldberg of Arsenal Capital Partners.

Black Patients Have Greater Risk of Dying From GVHD Than White Patients

The retrospective analysis found Black patients were more likely to develop severe graft versus host disease (GVHD) and have a higher risk of nonrelapse mortality than White patients after hematopoietic stem cell transplantation.

OpenAI’s Fund-Raising Talks Could Value Company at $150 Billion

The San Francisco start-up hopes to raise $6.5 billion as part of an aggressive push for more investment.

Dr.Evidence Unveils Major Enhancements to AI-enabled Landscape Intelligence Platform for Life Sciences

Dr.Evidence announced significant enhancements to further accelerate clients’ time-to-market for new drugs and indications and de-risk the possibility of missing critical precedent from the market to support a successful path to approval.

Archbow Consulting on LinkedIn

In an interview with Pharmaceutical Commerce Magazine Editor, Nicholas Saraceno, Archbow Consulting Vice President Meghan Mullooly, outlines the various #digitalsolutions available to drive efficiencies when delivering #PatientServices.

Stay tuned for Part II of their interview!

#pharma #biotech #HUB

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs